Key points from article :
Although current research gives promise to metformin as an anti-aging drug, there are still concerns.
Changes in dosage turning the result from life-extending to life-ending.
About 25% of patients treated with metformin have gastrointestinal side effects.
Chronic use causes vitamin B12 deficiency.
Gender influences drug effectiveness.
Metformin in Longevity Study (MILES) - 14 people aged >70 randomised to take metformin for 6 weeks. Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) will evaluate the performance of metformin in reducing CVD risks
The Targeting Aging with Metformin (TAME) trial - designed to enrol 3000 subjects.
Test whether metformin delays age-related diseases.
The TAME trial may make metformin the first approved drug for anti-aging.
The shift in the notion of aging will enable future anti-aging clinical to trials proceed with much more ease.
